Dr. Laura Ferraiuolo
Reader in Translational Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK
Dr. Laura Ferraiuolo was trained in Biotechnology at the University of Milan, Italy and joined the Department of Neuroscience at the University of Sheffield, UK in 2005 for her PhD, on a MND Association Prize studentship. Next, Dr. Ferraiuolo won the Peake Fellowship to investigate the crosstalk between motor neurons and astrocytes in motor neuron disease (MND) in Sheffield at the Institute for Translational Neuroscience. From 2012 to 2014, Dr. Ferraiuolo worked on glia and gene therapy in Columbus, Ohio, USA on a prestigious International Outgoing Marie Curie Fellowship funded by the EU. In 2014, Dr. Ferraiuolo returned to Sheffield to complete her Marie Curie Fellowship on the role of oligodendrocytes in MND. Since then, she has established her research group at SITraN, focussing on modelling the role of human glial cells in neurodegeneration and aging.
Prof. Mark A. Rubin
MD, Professor, Principal Investigator, and Director of the Department for BioMedical Research (DBMR), University of Bern, Switzerland.
Prof. Mark Rubin is a recognized world-renown leader in prostate cancer genomics and pathology, and precision medicine. Prof. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Furthermore, Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. Prof. Rubin founded the Englander Institute for Precision Medicine and, more recently, the Bern Center for Precision Medicine (BCPM).
Prof. Dr. Hinrich Schulenburg
Chair, Department of Evolutionary Ecology and Genetics, University of Kiel
Max-Planck Fellow at the MPI for Evolutionary Biology in Ploen, Germany
Prof. Hinrich Schulenburg is Spokesman of the Kiel Evolution Center, the Research Training Group on Translational Evolutionary Research (RTG 2501 TransEvo), and also the International Max-Planck Research School (IMPRS) for Evolutionary Biology. In addition, Prof. Schulenburg is Vice-Speaker of the Collaborative Research Center on the Origin and Function of Metaorganisms (CRC 1182) and the Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG). Furthermore, Prof. Schulenburg is a member of the Steering Committee of Kiel Life Science (KLS) and the Excellence Cluster on Precision Medicine in chronic Inflammation (PMI).
Prof. Dr. Giulio Superti-Furga
Scientific Director CeMM
Professor for Medical Systems Biology, Medical University of Vienna, Austria
Prof. Giulio Superti-Furga was trained in molecular biology at the University of Zurich, Genentech, IMP Vienna and EMBL Heidelberg. As the Scientific Director at CeMM since 2005, Prof. Superti-Furga aims to bridge the gap between biology and medicine, experiments with computation, discovery with translation, and science with society and the arts, to improve medicine for the benefit of patients. Recent interests include innovative functional precision medicine approaches and the role of the human transportome in pathophysiology and drug discovery. Prof. Superti-Furga co-founded five biotech startups, obtained four ERC grants and has published more than 200 papers.
Prof. Dr. Dr. Kerstin Noëlle Vokinger
Assistant Professor for Public Law and Digitalization
Health Law and Regulatory Sciences, University of Zurich, Switzerland
Kerstin Noëlle Vokinger is a Professor for Public Law and Digitalization at the University of Zurich. She is also an Affiliated Faculty at Harvard Medical School and a Faculty Associate at the Berkman Klein Center for Internet and Society at Harvard University. Kerstin studied in parallel medicine and law at the University of Zurich and Harvard Law School. She obtained a PhD at the University of Zurich and was a Postdoc Fellow at Harvard Medical School. Kerstin focuses interdisciplinary on questions and challenges at the intersection of law - medicine - technology. She also advises international organizations and governmental institutions in her areas of expertise.
Prof. Dr. Carolina Wählby
Professor in Quantitative Microscopy, Department of Information Technology, Division of Visual Information and Interaction, Uppsala University, Sweden
Prof. Carolina Wählby was trained in Molecular Biotechnology at the Karolinska Institute in Stockholm, Sweden, and did her PhD research in digital image processing at Uppsala University. In 2003, Prof. Wählby did a postdoc on genetics and pathology, with emphasis on methods development, after which she joined the Broad Institute of Harvard and MIT in USA in 2009, where she worked with algorithms for analysis of large scale experiments on model organisms to evaluate the effect of novel drugs. Prof. Wählby returned to Sweden and SciLifeLab in 2014 and became full professor in quantitative microscopy. Her research group develops computational image analysis approaches based on AI and deep learning for extracting information from microscopy images, with projects ranging from large-scale cell-based screens for drug development to in situ RNA sequencing.